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Electrospray time-of-flight mass spectrometry was used to quantitatively determine the
dissociation constant of chorismate mutase and a transition state analogue inhibitor. This
system presents a fairly complex stoichiometry because the native protein is a homotrimer
with three equal and independent substrate binding sites. We can detect the chorismate
mutase trimer as well as chorismate mutase-inhibitor complexes by choosing appropriate
conditions in the ESI source. To verify that the protein-inhibitor complexes are specific,
titration experiments with different enzyme variants and different inhibitors were performed.
A plot of the number of bound inhibitors versus added inhibitor concentration revealed
saturation behavior with 3:1 (inhibitor:functional trimer) stoichiometry for the TSA. The soft
ESI conditions, the relatively high protein mass of 43.5 kDa, and the low charge state (high m/z)
result in broad peaks, a typical problem in analyzing noncovalent protein complexes. Due to
the low molecular weight of the TSA (226 Da) the peaks of the free protein and the protein with
one, two or three inhibitors bound cannot be clearly resolved. For data analysis, relative peak
areas of the deconvoluted spectra of chorismate mutase-inhibitor complexes were obtained by
fitting appropriate peak shapes to the signals corresponding to the free enzyme and its
complexes with one, two, or three inhibitor molecules. From the relative peak areas we were
able to calculate a dissociation constant that agreed well with known solution-phase data. This
method may be generally useful for interpreting mass spectra of noncovalent complexes that
exhibit broad peaks in the high m/z range. (J Am Soc Mass Spectrom 2003, 14, 1470–1476) ©
2003 American Society for Mass Spectrometry
With the rapid progress in genomic sequencingand proteomics, noncovalent interactions ofproteins with their binding partners are be-
coming a major focus of attention. Especially in drug
development, where large libraries of ligands (e.g.
inhibitors) are often screened, a facile method for deter-
mining relative binding strengths with low substance
consumption is desirable.
Soft ionization mass spectrometry, such as electros-
pray ionization (ESI), is able to provide useful informa-
tion about noncovalent assemblies involving biological
macromolecules, including their complexes with small
ligands or inhibitors. Numerous studies have been
published on this topic, and a number of good reviews
have appeared [1–3]. Increasingly, the question of
whether dissociation constants of noncovalent com-
plexes can be determined by mass spectrometry is being
addressed (for a review see [4]). Because mass spectro-
metry employs gas-phase ions, conditions must be
found such that the complexes survive the desolvation
and ionization processes. If successful, the mass spec-
trometer can be considered as a detector for solution-
phase chemistry. Several methods have already been
published where noncovalent solution-phase interac-
tions have been analyzed quantitatively by mass spec-
trometry, including mass spectrometrically detected
melting curves [5], competition studies [6–8], and titra-
tion experiments [9–14]. Only a small number of studies
have appeared in the literature reporting the quantita-
tive investigation of protein inhibition by mass spectro-
metry [6, 8–10]. Among these, the studies by Greig et al.
[10] and Ayed et al. [11] involved interactions with
larger proteins/enzymes.
The most obvious advantages of mass spectrometry
include the possibility of obtaining the mass and stoi-
chiometry of a complex directly, short measurement
times, and the small amount of analyte required. It
could represent a useful method for determining bind-
ing constants of mutant proteins, where classical activ-
ity measurements cannot distinguish between residual
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activity of the mutant and activity due to wild type
enzyme still present as an impurity. A difficulty of mass
spectrometry using very soft ionization is that adducts
from solvent and/or buffer can survive the ionization
process and broaden the signals such that it becomes
difficult or impossible to distinguish small ligand ad-
ducts in the data. We addressed this problem by a new
data evaluation procedure.
The system studied here is the enzyme chorismate
mutase (E.C. 5.4.99.5) from Bacillus subtilis (BsCM), a
model for protein assembly as well as ligand binding.
BsCM catalyzes the rearrangement of chorismate to
prephenate, the first committed step in the biosynthesis
of the aromatic amino acids phenylalanine and tyrosine.
Since chorismate mutases are found in bacteria, fungi,
and higher plants, designing and screening inhibitors
for this enzyme might be of importance for the devel-
opment of new herbicides and antibacterial therapeu-
tics. The structure and function of BsCM are well
characterized. The crystal structure shows a homotrim-
eric pseudo--barrel surrounded by -helices with
three solvent-accessible binding sites at the subunit
interfaces [15]. As has been shown in solution the three
binding sites are all equal and independent [16]. A
BsCM monomer has a molecular weight of 14,489 Da,
leading to a molecular weight of 43,467 Da for the
functional trimer. Throughout this paper, the abbrevia-
tion BsCM represents the functional trimeric enzyme.
Several inhibitors have been reported for chorismate
mutases, including a transition state analogue (TSA)
designed by Bartlett and coworkers [17], which is used
in this study. This system allows us to investigate the
stability of the noncovalent trimer as well as the stabil-
ity of BsCM-inhibitor complexes in the gas phase.
Experimental
Instrumentation
All experiments were conducted on a prototype elec-
trospray orthogonal injection time-of-flight mass spec-
trometer from Agilent (Palo Alto, CA). It consists of a
commercial electrospray interface (Agilent), two skim-
mers, and an octopole ion guide for collisional cooling.
The ions are extracted orthogonally by a pulsed extrac-
tion field at a repetition rate of 4 kHz. The ions are
guided via a single stage reflectron to the detector (ETP
Electron Multipliers Pty Ltd. Ermington, Australia). The
detector signal is amplified and digitized with a com-
puter (Hewlett Packard, Palo Alto, CA) at a sampling
frequency of 250 MHz. The mass resolution of the
instrument is around 1100 in the mass range employed
here. Infusion rates of 1 to 5 l/min with a pneumati-
cally-assisted ESI source were used. The spray poten-
tials were between 2700 and 3000 V. The source condi-
tions of the instrument were optimized for the transfer
of high molecular weight ions and for gentle desolva-
tion conditions by adjusting the different source and
transfer potentials. Spectra were recorded in positive
mode with a repetition rate of 4 kHz. 1,000,000 tran-
sients per spectrum were summed and transferred to a
PC for further processing. The potential applied to the
exit of the transfer capillary is variable and is referred to
Vex below; the potential at the first skimmer is Vsk1.
Chorismate Mutases
Wild-type BsCM was produced in E. coli and purified
as described [18]. The truncated mutant BsCM1–120 was
generated by PCR amplification of the gene segment
encoding residues 1–120 of BsCM using plasmid
pKET3-W [19] as the template and T7PRO2 (TAATAC-
GACTCACTATAGGG) and SVSF-7-L121* (AACTC-
CTCGAGTTAGCTTAAATCGGGCCTCAATA) as the
forward and reverse primers, respectively. The nucleo-
tides for the stop codon replacing the triplet encoding
Leu121 are shown in bold. The gene fragment was
purified, digested with BsrGI and XhoI, and ligated into
the acceptor fragment obtained by digesting pKET3-W
with the same enzymes. The insert in the resulting
plasmid, pAK-L121*, was verified by sequencing using
primer 04-T7TR (CAGCAGCCAACTCAGCTTC-
CTTTC) [20]. The chorismate mutase deficient E. coli
strain KA13 [21] transformed with pAK-L121* afforded
40 mg of purified BsCM1–120 per 1 L of culture. The
molecular weight of the mutant protein was confirmed
by ESI-MS (experimental result 13,691  2 Da; calcu-
lated 13,689 Da). No impurities were observed by
polyacrylamide gel electrophoresis. ESI-MS showed
that the N-terminal methionine is partially removed, as
is typical for bacterial proteins, but this has no effect on
the enzymatic activity. However, it leads to a low-mass
shoulder that can be seen in some of the ESI mass
spectra presented below.
Prior to ESI-MS measurements, the proteins were
desalted three times by gel filtration (NAP-5 column,
Amersham Pharmacia Biotech, Uppsala, Sweden). ESI
measurements were made with a concentration of 10
M protein monomer, corresponding to 3.3 M BsCM
in the active (trimeric) form, dissolved in 10 to 20 mM
triethyl ammonium bicarbonate buffer (pH  8). Pro-
tein concentration was determined by UV spectroscopy
prior to desalting. Recovery factors of the desalting
columns were 97% such that uncorrected values of
protein concentration were used.
Inhibitors
TSA was synthesized according to literature procedures
[17]. In addition, adamantyl-1-phosphonate (AP), syn-
thesized according to a published procedure [22], was
used as a very weak BsCM inhibitor.
Inhibition Assays
The enzymes were assayed as previously described [18]
at pH  7.5 in 50 mM potassium phosphate buffer or in
triethylammonium bicarbonate (TEAB) buffer, respec-
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tively. The Kd values were calculated from the slope of
the line obtained by plotting [enzyme]/v0 versus the
inhibitor concentration using the equation, Kdd  Km/
(kcat * [substrate] * slope), where Km and kcat are the
independently measured Michaelis and catalytic rate
constants obtained in the absence of inhibitor [kcat
(wtBsCM)  46 s1; Km  100 M; kcat (BsCM
1–120)  44
s1; Km  1010 M]. The enzyme was used at a
concentration of 10 nM, the substrate concentration
between 25 and 400 M for BsCM and between 20 and
2000 M for BsCM1–120. The inhibitor concentration was
varied between 0.5 and 50 M depending on the
experimentally determined Kd value. Kd values ob-
tained by this method are reported per binding pocket,
whereas in our analysis of the mass spectrometric data,
Kd values refer to the concentration of the total trimer
concentrations. Thus, the Kd values obtained by mass
spectrometry were divided by a factor of 3 for compar-
ison with literature and measured solution-phase data.
Results and Discussion
Detection of the Chorismate Mutase Trimer
A prerequisite for the detection of specific noncovalent
interactions between a protein and bound inhibitors is
the preservation of a near-native structure of the protein
during passage from solution phase to the gas phase. As
the active form of BsCM is a homotrimer, it is necessary
to detect the trimer in the mass spectrum. It has been
reported [23] that multiply charged ions generated in
TEAB solution are significantly more stable than those
formed in conventional buffers such as ammonium
bicarbonate or acetate. Our experience has confirmed
this observation, and we generally used TEAB at a
concentration of 10 to 20 mM. Spectrophotometric as-
says showed that BsCM retains full activity in this
buffer. The BsCM trimer was detected at low Vsk1. With
increasing Vsk1 it dissociated into monomers that are
not observed in solution under physiological conditions
(Figure 1). However, peaks corresponding to dimers
were in no case detected. Likewise no signals for
tetramers or pentamers could be observed under any
conditions. Both observations speak against formation
of unspecific clusters of BsCM monomers, suggesting
that specific native-like protein-protein interactions ac-
count for the observation of trimeric species at low Vsk1.
Together with the binding constants determined by
mass spectrometric methods described later in this
work which are comparable to solution-phase binding
constants, these findings show that the detected trimer
is indeed the result of specific interactions.
Detection of Trimer-Inhibitor Complexes
To be able to detect a weak noncovalent interaction,
very soft conditions in the ESI source must be chosen in
order to prevent the complex from dissociating. How-
ever, reasonable desolvation of the complexes is still
necessary to obtain a satisfactory signal-to-noise ratio
and to avoid extensive adduct formation. A compro-
mise must thus be found for the operating conditions of
the ESI source. Figure 2 shows the [M  8H]8 peak of
the BsCM trimer from spectra of a solution (3.3 M
BsCM and 10 M TSA in 10 mM TEAB) recorded at
different Vex and Vsk1 values. At high voltages, corre-
sponding to harsher conditions, the peak intensitiy is
very good, and the mass is only slightly larger than the
calculated mass of a bare BsCM trimer (Spectrum A).
The small mass difference is due to incomplete desol-
vation of the native trimer and buffer molecule adducts,
as previously described [24]. Decreasing Vex and Vsk1,
and hence going to softer conditions, gives a clear shift
to higher mass. The peak also becomes broader, but
shows partial resolution of the different BsCM-inhibitor
complexes (Spectrum B). With even softer conditions
the peak shifts further in the direction of higher mass
(Spectrum C) with the maximum close to the theoretical
mass of a BsCMI3 complex, while the resolution of the
different complex peaks, however, is lost. Interestingly,
Figure 1. ESI-TOF mass spectra of a solution of 3.3 M BsCM. By
decreasing Vex and Vsk1 and hence going to softer conditions,
peaks corresponding to the trimer (represented by an asterisk)
become the only species detected. Peaks corresponding to the
monomer (represented by an open triangle) disappear.
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a further decrease in Vex and Vsk1 does not result in a
further shift towards higher mass but only to a loss in
signal intensity (Spectrum D). In the following titration
experiments we therefore chose the conditions used for
spectrum C since under these conditions the complex
does not appear to dissociate in the gas phase, while
signal intensity is still reasonable. It should be noted
that the monomeric enzyme subunit is not evident in
any of the spectra shown in Figure 2.
Titration Experiments with Different Inhibitors
and Chorismate Mutase Mutants
Before the binding strength of an inhibitor for an
enzyme can be determined, the specificity of the de-
tected complex must be verified. Since the mass is the
main observable in mass spectrometry, it cannot be
decided from one single measurement whether the
inhibitor is located in the binding pocket or simply
bound non-specifically to the surface of the protein. To
address this question we used a BsCM mutant in
addition to wild type BsCM, as well as the much
weaker AP inhibitor (Kd  4 mM). The mutant species,
called BsCM1–120, was shorter by the last seven C-
terminal amino acids in the sequence and exhibited
reduced enzyme activity and ligand affinity, as re-
ported previously for other randomly truncated BsCM
mutants [25].
A series of experiments was performed by varying
the concentration of the TSA or AP inhibitors in the
presence of 3.3 M BsCM or BsCM1–120. Since the peaks
corresponding to the free enzyme and its complexes
with one, two or three inhibitor molecules are not
clearly resolved, the statistical number of bound inhib-
itor molecules was determined. Spectra such as those
shown in Figure 2 were deconvoluted to represent the
1 charge state only, smoothed, and the average mass
at every inhibitor concentration was obtained. The mass
difference m between this average mass and the mass
of the free protein was then divided by the mass of the
inhibitor to yield the number of bound inhibitor mole-
cules. In Figure 3, the results for TSA/ BsCM, TSA/
BsCM1–120, and AP/BsCM are plotted against the added
inhibitor concentration. For wild type BsCM binding
TSA, this results in a saturation curve, the limit of which
at a 20-fold molar excess of inhibitor slightly exceeds
the theoretical maximum of three bound inhibitors. At
this excess and under these conditions (low salt concen-
trations) some nonspecific binding can apparently oc-
cur. However, we take the clear saturation behavior at a
value of three inhibitors per trimer as evidence for a
specific binding to the binding pocket. The curves for
TSA/BsCM1–120 and for AP/BsCM show a lower in-
crease in binding of inhibitor, which can be attributed to
weaker binding.
Calculation of Kd
The binding of the inhibitor to BsCM showed an
apparent dependence on the charge state, i.e. peak
intensity ratios of complex relative to bare enzyme
appeared to be different for every charge state. A
straightforward explanation for this observation is a
conformational change induced by the inhibitor, which
often leads to a change in the charge state distribution
in the ESI mass spectra. Consider, for example, a most
abundant charge state of [M  10H]10 for the naked
BsCM and a maximum charge state of [M  9H]9
Figure 2. ESI-TOF mass spectra ([M  8H]8 charge state) of a
solution of 3.3 M BsCM and 10 M TSA inhibitor at different
desolvation conditions. From top to bottom conditions become
increasingly softer: (a) Vex  250 V, Vsk1  138 V; (b) Vex  150 V,
Vsk1  83 V; (c) Vex  100 V, Vsk1  55 V; (d) Vex  50 V, Vsk1 
28 V. The vertical lines represent the mass of bare BsCM and the
calculated peak positions of BsCM with one, two and three
inhibitors bound. Note the mass shift towards the BsCMI3 com-
plex as the conditions become softer. The low-mass shoulder is
due to partial removal of N-terminal methionine, as is typical for
bacterial proteins. Inset: Structure of the TSA inhibitor.
Figure 3. Plot of number of bound inhibitors against inhibitor
concentration for TSA /BsCM (filled circles) and TSA /BsCM1–120
(open circles), and AP/BsCM (open triangles). BsCM concentra-
tion was 3.3 M in all cases. The number of bound inhibitors was
determined from the deconvoluted spectra as described in the
text.
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after binding of the inhibitor. An overlay of the two ESI
mass spectra will then result in different intensity ratios
at every peak, i.e. in an apparent charge state dependent
inhibitor binding. The correct way to deal with this is to
calculate dissociation constants from the deconvoluted
spectrum (representing the charge state z  0, i.e.,
without any protons attached), thus taking into account
all charge states observed in the spectrum.
The resulting deconvoluted peaks of some selected
spectra are shown in Figure 4. To evaluate the data
quantitatively we need to be able to determine the
relative contributions of the free enzyme and the indi-
vidual complexes to the total peak area, i.e., the ratio of
BsCM/BsCMI, BsCMI/BsCMI2 or BsCMI2/BsCMI3.
Due to large, overlapping peaks, these ratios cannot be
read directly from the spectra. Therefore the data were
fitted in the following manner. First, the deconvoluted
peak of a spectrum of free BsCM was modeled by a
smoothing spline function as described in the appendix.
Then we assumed that the peaks of the protein-inhibitor
complexes differ only in their position on the mass scale
and their amplitude but not in their shape. This allows
the contribution of all four BsCM/BsCM-inhibitor spe-
cies to be determined from the shape of the previously
determined BsCM signal. For fitting the spectra, two
additional parameters were needed, one to account for
the baseline level and a scaling factor that accounts for
the absolute intensity of each spectrum. Since all bind-
ing sites are equal and independent and therefore do
not show any allosteric or cooperative effect [16], only a
single fitting parameter, a probability P that describes
the occupation of a binding site by an inhibitor, fully
determines the ratio of all four peaks (for details, see
appendix).
As can be seen in Figure 5, which depicts an example
of such a fit, the raw data are matched very well. At
higher inhibitor concentrations, starting from 50 M
which corresponds to a 15-fold excess, the fits were less
good, probably due to the onset of unspecific binding of
inhibitor to the enzyme. Therefore only data for inhib-
itor concentrations below 50 M were used to calculate
the Kd value. The fitting parameter affords the relative
peak areas for BsCM, BsCMI, BsCMI2, BsCMI3, allow-
ing a dissociation constant to be calculated for each
titration point as explained in the appendix. For the
wild type enzyme BsCM and the TSA inhibitor a Kd of
1.7  1 M was determined, which compares well with
the value of 1.0  0.2 M determined in the solution-
phase assay. In the literature values between 1.7 [26]
and 3 M [16] have been reported. For the truncated
enzyme BsCM1–120 and TSA we determined Kd to be 37
 6 M with our mass spectrometric method whereas a
standard solution assay gave 25  1.7 M. Again, the
Kd values determined by mass spectrometry and the
solution-phase assay are in good agreement. Systematic
errors can be introduced if the actual initial enzyme
concentration used for the measurements is lower than
stated, due to losses in the desalting process or precip-
itation while freezing and thawing the protein solu-
tions.
Conclusions
Broad peaks are often a problem when measuring
noncovalent complexes by ESI-MS. Since it is necessary
to maintain the native structure of the protein for
substrate or inhibitor binding, the number of charges
loaded on the protein is usually low, leading to high m/z
values where the instrumental mass resolution drops.
Figure 4. Deconvoluted ESI mass spectra of BsCM (top), BsCM
plus 2.5 M TSA (middle) and BsCM plus 10 M TSA (bottom).
BsCM concentration was 3.3 M. The vertical lines represent the
peak position of bare BsCM determined by ESI-MS and the
calculated peak positions of BsCM with one, two, and three
inhibitors bound.
Figure 5. Representative figure of the fitted mass spectra (for
details see text and appendix). The dashed line represents the
function fitted to the deconvoluted mass spectrum of bare BsCM.
The dotted lines are this function shifted by the inhibitor mass
zero, one, two, or three times. The solid line is the sum of these
four functions fitted to the deconvoluted spectra of BsCM plus 10
M TSA. BsCM concentration was 3.3 M.
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In addition, the preservation of weak noncovalent in-
teractions necessitates the use of very soft desolvation
conditions in the ESI source which leads to a further
increase in peak width due to adducts. In this study, we
overcame this problem by modeling the signal of non-
covalent protein-inhibitor complexes as the sum of four
single peaks derived from the signal of the “naked”
(trimeric) enzyme. In doing so we obtained dissociation
constants for BsCM and TSA as well as for BsCM1–120
and TSA. The absolute Kd values determined by MS are
in good agreement with solution-phase data.
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Appendix
A. Modeling of the Deconvoluted Peak of the
“Naked” Chorismate Mutase Trimer
To model the shape of the deconvoluted peak of the
“naked” trimer a function is needed which closely
follows the data but rejects the noise. We used a
“smoothing spline function” as described in reference
[27] to achieve the smoothest curve that lies within the
given tolerance of the measured data. Empirically, we
found that a tolerance corresponding to 1% of the total
amplitude gave satisfactory results for our data set.
B. Calculating the Ratio of Peaks
When binding sites are equal and independent as is the
case for BsCM [16] we can define a probability P of a
binding site being occupied by an inhibitor (0  P 
100%). The concentration of the various enzyme-inhib-
itor complexes can then be expressed as
[BsCM] 	1  P
3  BsCM]0 (1)
[BsCMI] 3  	1  P
2  P  [BsCM]0 (2)
[BsCMI2] 3  	1  P)  P
2  [BsCM]0 (3)
[BsCMI3] P
3  [BsCM]0 (4)
where the factor 3 accounts for the statistical permuta-
tions of the complex. Since [BsCM]0, the total enzyme
concentration, is known, the entire complex distribution
is defined by P. In other words, only a single fitting
parameter describes the relative peak areas.
C. Calculating Dissociation Constants
The dissociation constants were calculated based on the
general theory of multiple equilibria using only peak
ratios. For the three equilibria, three dissociation con-
stants Ki can be defined and expressed with the Kd for
binding to an individual site of the enzyme as follows
[28]:
K1  I  BsCM]/[BsCMI  1/3  Kd (5)
K2  I  BsCMI]/[BsCMI2  Kd (6)
K3  I  BsCMI2]/[BsCMI3  3  Kd (7)
where [I] is the free inhibitor concentration and the
peak ratios are given by
BsCM]/[BsCMI  	1  P
/	3  P
 (8)
BsCMI]/[BsCMI2  	1  P
/P (9)
BsCMI2]/[BsCMI3  3  	1  P
/P (10)
where P is obtained from the fit of the data.
The total concentrations of the enzyme, [BsCM]0, and
of the inhibitor, [I0], are given by
BsCM0  BsCM  BsCM  BsCMI
 BsCMI2  BsCMI3 (11)
I0  I  BsCMI  2*BsCMI2
 3  BsCMI3 (12)
By inserting eqs 8, 9, and 10 into eq 11 and solving for
[BsCM], and inserting eqs 8, 9, and 10 into eq 12 and
solving for [I] one gets
I  I0  BsCM0  3P (13)
By inserting eqs 9 and 13 into eq 6, Kd can be calculated
from one single measurement. Kd was determined for
seven titration points in the range from 0 to 50 M TSA
where satisfactory fits were obtained. From these seven
Kd values the standard deviation was calculated.
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